PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10063307-2	1999	METHODS: Thirty-two patients with CAH-B were treated with interferon alpha-2b(IFN alpha-2b) with prednisolone withdrawal and 30 control patients were treated with conventional hepatotonics for 6 months.	Prednisolone	97-109	interferon alpha 1	Homo sapiens	78-81	
16225652-7	2005	In conclusion, continuing prednisolone treatment during the entire duration of the induction phase with VMCP-IFN-alpha 2b did not improve outcome.	Prednisolone	26-38	interferon alpha 1	Homo sapiens	109-118	
10845671-1	2000	BACKGROUND/AIMS: The aim of this study was to understand the changes in the proportion of hepatitis B virus precore stop mutant during the course of prednisolone primed interferon (IFN) therapy.	Prednisolone	149-161	interferon alpha 1	Homo sapiens	181-184	
10845671-2	2000	METHODS: Three groups of patients were included: patients receiving prednisolone-primed IFN treatment (Group I, n=31), IFN treatment only (Group II, n=29), and placebo (Group III, n=25).	Prednisolone	68-80	interferon alpha 1	Homo sapiens	88-91	
10845671-10	2000	CONCLUSIONS: Our data suggest that prednisolone serves as a modulator to enhance elimination of precore stop mutant by IFN, which advocates the benefit of corticosteroid pretreatment in an area where the precore mutants are prevalent.	Prednisolone	35-47	interferon alpha 1	Homo sapiens	119-122	
15515704-5	2004	One year later, worsening of his hepatic condition required re-administration of IFN alpha after gradual decrease and discontinuation of prednisolone.	Prednisolone	137-149	interferon alpha 1	Homo sapiens	81-90	
10063307-7	1999	The levels of liver function test(LFT) in the patients with IFN alpha-2b treatment with prednisolone withdrawal were not different from the control patient group at pretreatment, but significantly lower than control patient group"s after treatment, regardless of response to IFN alpha-2b treatment with prednisolone withdrawal.	Prednisolone	88-100	interferon alpha 1	Homo sapiens	60-63	
10063307-7	1999	The levels of liver function test(LFT) in the patients with IFN alpha-2b treatment with prednisolone withdrawal were not different from the control patient group at pretreatment, but significantly lower than control patient group"s after treatment, regardless of response to IFN alpha-2b treatment with prednisolone withdrawal.	Prednisolone	303-315	interferon alpha 1	Homo sapiens	60-63	
10063307-9	1999	IFN alpha-2b treatment with prednisolone withdrawal may be regarded as one of the effective treatment modalities for the inhibition of disease progression in patients with CAH-B.	Prednisolone	28-40	interferon alpha 1	Homo sapiens	0-3	
1450506-3	1992	Recombinant human alpha-interferon (IFN) at a dose of 3 million units combined with melphalan and prednisolone was administrated.	Prednisolone	98-110	interferon alpha 1	Homo sapiens	18-40	
6696458-6	1984	IFN therapy combined with other agents, such as adenine arabinoside, prednisolone, etc.	Prednisolone	69-81	interferon alpha 1	Homo sapiens	0-3	
6178505-4	1982	Prednisolone, an inhibitor of phospholipase A2, at a concentration of 2 micrograms/ml inhibited the enhanced synthesis of PGE by IFN-pretreated cells.	Prednisolone	0-12	interferon alpha 1	Homo sapiens	129-132	
6178505-10	1982	Prednisolone and iodomethacin partially inhibited anti-cell growth activity of IFN, suggesting a possibility that IFN-inhibited cell growth was partly mediated by prostaglandin.	Prednisolone	0-12	interferon alpha 1	Homo sapiens	79-82	
6178505-10	1982	Prednisolone and iodomethacin partially inhibited anti-cell growth activity of IFN, suggesting a possibility that IFN-inhibited cell growth was partly mediated by prostaglandin.	Prednisolone	0-12	interferon alpha 1	Homo sapiens	114-117